Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASAP-C: Short Course HCV Therapy
NCT03480932Phase 3Completed
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Start
- Feb 2018
- Primary completion
- Nov 2018
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfa-2a in hepatitis C virus infection, sponsored by Johns Hopkins Bloomberg School of Public Health. Started Feb 2018; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NCT03480932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480932.